Modulating AAV-Mediated Immune Response Depending on Route of Administration & Underlying Disease
Time: 11:30 am
day: Day 2 Tracks 2 AM
Details:
- Consideration for prophylactic immunomodulation/immunosuppression depending on AAV-based gene therapy route of administration
- Finding a subtle balance between safe immunomodulation and sufficient suppression of AAV-driven immune response
- Additional safety considerations as they relate to immunosuppression when treating frail patient populations
